SOUTH SAN FRANCISCO, Calif. — September 10, 2026
Lyell Immunopharma, Inc. announced the successful completion of the planned technology transfer for LYL273 to its LyFE Manufacturing Center™ in Bothell, Washington, following review by the U.S. Food and Drug Administration (FDA). LYL273 is a guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate being evaluated in patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC). The transfer brings an improved manufacturing process and updated analytical methods into LyFE, which is designed to enhance manufacturing performance and increase production capacity. Meanwhile, the ongoing Phase 1/2 CARABiNER trial continues to enroll patients, with the company focused on determining the recommended Phase 2 dose and optimizing the safety management plan. Lyell now expects additional clinical data and an End-of-Phase 1 meeting with the FDA in 2027, making manufacturing readiness and clinical dose optimization key priorities for the LYL273 program.
Improved Manufacturing Supports LYL273 Clinical Development
The LyFE technology transfer represents an important operational milestone as Lyell prepares LYL273 for continued clinical development. The improved manufacturing process and updated analytical methods are intended to strengthen manufacturing performance while supporting increased capacity at the company’s proprietary facility. LyFE is designed with commercial launch capability and is expected to have capacity to manufacture more than 1,200 CAR T-cell doses annually. Incorporating the updated process into the ongoing clinical program allows Lyell to evaluate patients receiving LYL273 manufactured under the improved conditions while advancing dose escalation. The company is also activating additional clinical sites for the expansion phase of CARABiNER, responding to interest from experienced investigators. Establishing a scalable manufacturing infrastructure alongside clinical dose optimization is particularly important for an autologous CAR T-cell therapy, where consistent production and analytical characterization are critical components of development and eventual commercialization.
CARABiNER Advances Safety and Dose Optimization
The Phase 1/2 CARABiNER trial is evaluating LYL273 in patients with third- or later-line relapsed/refractory metastatic colorectal cancer, with the current expansion focused on defining the recommended Phase 2 dose and refining management of treatment-related safety events. LYL273 incorporates CD19 CAR expression and controlled cytokine release alongside its GCC-targeting design, with the goal of improving CAR T-cell expansion, immune-cell infiltration and tumor-cell killing within the hostile solid-tumor microenvironment. Lyell previously reported safety findings showing that gastrointestinal prophylaxis using infliximab, vedolizumab and budesonide reduced Grade ≥2 diarrhea or colitis from 55% without prophylaxis to 10% with prophylaxis. The company is continuing dose escalation while incorporating clinical experience from the improved LyFE manufacturing process and refining the prophylaxis strategy to calibrate immune suppression. These efforts are intended to establish a more defined therapeutic and safety profile before the program advances into Phase 2 development.
Advertisement
Lyell Prepares LYL273 for 2027 Regulatory Milestones
Lyell Immunopharma is now aligning its manufacturing, clinical and regulatory activities around a broader LYL273 development package expected in 2027. The company plans to generate additional clinical data from CARABiNER and use the results to support an End-of-Phase 1 discussion with the FDA. The regulatory interaction is expected to address the recommended Phase 2 dose, safety management and the future clinical development strategy for LYL273. The program is part of Lyell’s broader effort to develop next-generation CAR T-cell therapies capable of overcoming limitations associated with solid tumors, including T-cell exhaustion and an immunosuppressive tumor microenvironment. Completion of the LyFE transfer strengthens the manufacturing foundation of LYL273 at the same time that patient enrollment continues, creating an integrated path toward dose selection, safety optimization and later-stage development. With additional clinical data and FDA discussions expected in 2027, LYL273 remains a key program in Lyell’s strategy to extend CAR T-cell therapy into solid tumors.
Source: Lyell Immunopharma, press release
